Skip to main content

Published locations for Prostate-Specific Antigen Decline >50% After 4 Weeks of Treatment Is an Indicator of Better Progression Free and Overall Survival Both With Abiraterone and Enzalutamide in Metastatic Castrate Resistant Prostate Cancer

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Prostate-Specific Antigen Decline >50% After 4 Weeks of Treatment Is an Indicator of Better Progression Free and Overall Survival Both With Abiraterone and Enzalutamide in Metastatic Castrate Resistant Prostate Cancer

User login

  • Reset your password
  • /content/prostate-specific-antigen-decline-50-after-4-weeks-treatment-indicator-better-progression
  • /fedprac/article/227903/oncology/prostate-specific-antigen-decline-50-after-4-weeks-treatment
  • /fedprac/avaho/article/227903/oncology/prostate-specific-antigen-decline-50-after-4-weeks-treatment